Swelling attacks affecting the airway usually occur in hereditary angioedema patients between the ages of 20 and 30 —…
Articles by Patricia Inácio, PhD
Switching from under-the-skin injections to oral pills of Orladeyo (berotralstat), a preventive treatment, can be done without the need…
Over a third of hereditary angioedema patients continue to experience an unpredictable rate of annual attacks, including those on…
Patients with hereditary angioedema (HAE) are willing to try new therapies that can effectively lessen disease burden with less…
Adalvo has completed a mandatory requirement for a marketing authorization in the European Union for its generic version of…
The Israeli Ministry of Health has agreed to review, under an accelerated process, a marketing application for Orladeyo (berotralstat),…
Spain has added Ruconest (conestat alfa), Pharming’s treatment for acute attacks of hereditary angioedema (HAE), to its list…
Ahead of this year’s Rare Disease Week on Capitol Hill, held virtually July 14–22, the EveryLife Foundation will…
Pharma and patient organizations came together this year in celebration of the 10th annual HAE Awareness Day — set…
Haegarda is now available to adolescent and adult hereditary angioedema (HAE) patients across Canada for the prevention of HAE…